# Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy

Source: https://onco.cc/trials/nct00100243/  
OnCo record `nct00100243` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Abarelix in Prostate cancer, run by PRAECIS Pharmaceuticals Inc., completed.

## Summary

Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy is a phase 2 interventional study registered as NCT00100243 by PRAECIS Pharmaceuticals Inc., with 22 participants recorded, started 2004-05. Interventions recorded: Plenaxis. Conditions recorded: Prostate Cancer.

Linked to the drug Abarelix because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00100243
- Phase: 2
- Setting: Phase 2 Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy
- Sponsor: PRAECIS Pharmaceuticals Inc.
- Enrolled: 22

## Sources

- ClinicalTrials.gov NCT00100243: https://clinicaltrials.gov/study/NCT00100243

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Abarelix](https://onco.cc/drugs/abarelix/)

---
JSON: https://onco.cc/api/v1/entities/nct00100243.json